A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults
Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 re...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1987 |
|---|
| Umfang: |
3 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Cancer chemotherapy and pharmacology - 1978, 19(1987) vom: Feb., Seite 169-171 |
| Übergeordnetes Werk: |
volume:19 ; year:1987 ; month:02 ; pages:169-171 ; extent:3 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202995259 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202995259 | ||
| 003 | DE-627 | ||
| 005 | 20230505223650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1987 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202995259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| 264 | 1 | |c 1987 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Barnett, Michael J. |4 oth | |
| 700 | 1 | |a Rohatiner, Ama Z. S. |4 oth | |
| 700 | 1 | |a Ganesan, Trivadi S. |4 oth | |
| 700 | 1 | |a Richards, Michael A. |4 oth | |
| 700 | 1 | |a Miller, Ann |4 oth | |
| 700 | 1 | |a Lister, T. Andrew |4 oth | |
| 773 | 0 | 8 | |i in |t Cancer chemotherapy and pharmacology |d 1978 |g 19(1987) vom: Feb., Seite 169-171 |w (DE-627)NLEJ188987932 |w (DE-600)1458488-8 |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:1987 |g month:02 |g pages:169-171 |g extent:3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00254573 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 1987 |c 2 |h 169-171 |g 3 | ||
| matchkey_str |
article:14320843:1987----::paeitdohgdsctsnaaioienhtetetfc |
|---|---|
| hierarchy_sort_str |
1987 |
| publishDate |
1987 |
| allfields |
(DE-627)NLEJ202995259 DE-627 ger DE-627 rakwb eng A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. Springer Online Journal Archives 1860-2002 Barnett, Michael J. oth Rohatiner, Ama Z. S. oth Ganesan, Trivadi S. oth Richards, Michael A. oth Miller, Ann oth Lister, T. Andrew oth in Cancer chemotherapy and pharmacology 1978 19(1987) vom: Feb., Seite 169-171 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:19 year:1987 month:02 pages:169-171 extent:3 http://dx.doi.org/10.1007/BF00254573 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 19 1987 2 169-171 3 |
| spelling |
(DE-627)NLEJ202995259 DE-627 ger DE-627 rakwb eng A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. Springer Online Journal Archives 1860-2002 Barnett, Michael J. oth Rohatiner, Ama Z. S. oth Ganesan, Trivadi S. oth Richards, Michael A. oth Miller, Ann oth Lister, T. Andrew oth in Cancer chemotherapy and pharmacology 1978 19(1987) vom: Feb., Seite 169-171 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:19 year:1987 month:02 pages:169-171 extent:3 http://dx.doi.org/10.1007/BF00254573 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 19 1987 2 169-171 3 |
| allfields_unstemmed |
(DE-627)NLEJ202995259 DE-627 ger DE-627 rakwb eng A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. Springer Online Journal Archives 1860-2002 Barnett, Michael J. oth Rohatiner, Ama Z. S. oth Ganesan, Trivadi S. oth Richards, Michael A. oth Miller, Ann oth Lister, T. Andrew oth in Cancer chemotherapy and pharmacology 1978 19(1987) vom: Feb., Seite 169-171 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:19 year:1987 month:02 pages:169-171 extent:3 http://dx.doi.org/10.1007/BF00254573 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 19 1987 2 169-171 3 |
| allfieldsGer |
(DE-627)NLEJ202995259 DE-627 ger DE-627 rakwb eng A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. Springer Online Journal Archives 1860-2002 Barnett, Michael J. oth Rohatiner, Ama Z. S. oth Ganesan, Trivadi S. oth Richards, Michael A. oth Miller, Ann oth Lister, T. Andrew oth in Cancer chemotherapy and pharmacology 1978 19(1987) vom: Feb., Seite 169-171 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:19 year:1987 month:02 pages:169-171 extent:3 http://dx.doi.org/10.1007/BF00254573 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 19 1987 2 169-171 3 |
| allfieldsSound |
(DE-627)NLEJ202995259 DE-627 ger DE-627 rakwb eng A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. Springer Online Journal Archives 1860-2002 Barnett, Michael J. oth Rohatiner, Ama Z. S. oth Ganesan, Trivadi S. oth Richards, Michael A. oth Miller, Ann oth Lister, T. Andrew oth in Cancer chemotherapy and pharmacology 1978 19(1987) vom: Feb., Seite 169-171 (DE-627)NLEJ188987932 (DE-600)1458488-8 1432-0843 nnns volume:19 year:1987 month:02 pages:169-171 extent:3 http://dx.doi.org/10.1007/BF00254573 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 19 1987 2 169-171 3 |
| language |
English |
| source |
in Cancer chemotherapy and pharmacology 19(1987) vom: Feb., Seite 169-171 volume:19 year:1987 month:02 pages:169-171 extent:3 |
| sourceStr |
in Cancer chemotherapy and pharmacology 19(1987) vom: Feb., Seite 169-171 volume:19 year:1987 month:02 pages:169-171 extent:3 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Cancer chemotherapy and pharmacology |
| authorswithroles_txt_mv |
Barnett, Michael J. @@oth@@ Rohatiner, Ama Z. S. @@oth@@ Ganesan, Trivadi S. @@oth@@ Richards, Michael A. @@oth@@ Miller, Ann @@oth@@ Lister, T. Andrew @@oth@@ |
| publishDateDaySort_date |
1987-02-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987932 |
| id |
NLEJ202995259 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202995259</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505223650.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202995259</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barnett, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rohatiner, Ama Z. S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ganesan, Trivadi S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richards, Michael A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miller, Ann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lister, T. Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">19(1987) vom: Feb., Seite 169-171</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:169-171</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00254573</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">1987</subfield><subfield code="c">2</subfield><subfield code="h">169-171</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987932 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0843 |
| topic_title |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m j b mj mjb a z s r azs azsr t s g ts tsg m a r ma mar a m am t a l ta tal |
| hierarchy_parent_title |
Cancer chemotherapy and pharmacology |
| hierarchy_parent_id |
NLEJ188987932 |
| hierarchy_top_title |
Cancer chemotherapy and pharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987932 (DE-600)1458488-8 |
| title |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| spellingShingle |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| ctrlnum |
(DE-627)NLEJ202995259 |
| title_full |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| journal |
Cancer chemotherapy and pharmacology |
| journalStr |
Cancer chemotherapy and pharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1987 |
| contenttype_str_mv |
zzz |
| container_start_page |
169 |
| container_volume |
19 |
| physical |
3 |
| format_se |
Elektronische Aufsätze |
| title_sort |
a phase ii study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| title_auth |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| abstract |
Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. |
| abstractGer |
Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. |
| abstract_unstemmed |
Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults |
| url |
http://dx.doi.org/10.1007/BF00254573 |
| remote_bool |
true |
| author2 |
Barnett, Michael J. Rohatiner, Ama Z. S. Ganesan, Trivadi S. Richards, Michael A. Miller, Ann Lister, T. Andrew |
| author2Str |
Barnett, Michael J. Rohatiner, Ama Z. S. Ganesan, Trivadi S. Richards, Michael A. Miller, Ann Lister, T. Andrew |
| ppnlink |
NLEJ188987932 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| up_date |
2024-07-06T09:29:40.663Z |
| _version_ |
1803821442047934464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202995259</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505223650.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202995259</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barnett, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rohatiner, Ama Z. S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ganesan, Trivadi S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richards, Michael A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miller, Ann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lister, T. Andrew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Cancer chemotherapy and pharmacology</subfield><subfield code="d">1978</subfield><subfield code="g">19(1987) vom: Feb., Seite 169-171</subfield><subfield code="w">(DE-627)NLEJ188987932</subfield><subfield code="w">(DE-600)1458488-8</subfield><subfield code="x">1432-0843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:169-171</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00254573</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">1987</subfield><subfield code="c">2</subfield><subfield code="h">169-171</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.400646 |